Lovemore Mapahla

Mr. Lovemore Mapahla

orcid

Research Focus & Metrics

Representative Publications

View All Publications
26 July 2022 in BMC Infectious Diseases
Verified
Journal Article
Open access
PDF file
LALydia Atuhaire
Lydia Atuhaire
CSConstance S. Shumba
Constance S. Shumba
LMLovemore Mapahla
Lovemore Mapahla
PNPeter S. Nyasulu
Peter S. Nyasulu
Background: Patient retention in care and sustained viral load suppression are a cornerstone to improved health and quality of life, among people living with HIV. However, challenges of retention on ART remain among female sex workers (FSWs). We report lost to follow up (LTFU), viral load suppression, and the associated factors among FSWs that access HIV treatment at primary health care facilities in Kampala. Methods: We retrospectively abstracted and analysed patient management data of HIV positive FSWs who enrolled in care between January 2018 to December 2020. LTFU was defined as failure of a FSW to return for treatment at least 90 days from the date of their last clinic appointment. We defined viral suppression as having a last viral load of ≤ 1000 copies/ml preceding data abstraction. Data were analysed using Stata 15.1 software. Results: A total of 275 FSWs were included in our study sample. We found low retention of 85.1% (n = 234) at six months, corresponding to LTFU of 14.9 (n = 41) within the same period. Retention decreased with duration of being in care up to 73.5% (n = 202) at 24 months, and this translates to LTFU of 26.5% (n = 73). Viral load testing coverage was 62% (n = 132) and of these, 90.9% (n = 120) were virally suppressed. Factors associated with LTFU in univariable logistic regression; and viral load suppression in multivariable logistic regression models were; having a telephone contact (OR: 0.3, 95% CI: 0.1–0.9 p = 0.031), having enrolled in HIV care aged ≥ 35 years (OR: 0.5, 95% CI: 0.2–1.0 p = 0.048), (OR:0.03, 95%CI: 0.00–0.5, p = 0.016); and having good ART adherence (OR: 0.2, 95% CI: 0.1–0.5 p = 0.001), (OR:24.0, 95% CI: 3.7–153.4 p = 0.001) respectively. Having good ART adherence remained statistically significant (OR: 0.2, 95% CI: 0.08–0.53 p = 0.001) in multivariable logistic regression for LTFU. Conclusion: This study found low retention among HIV diagnosed FSWs in care. Viral load suppression was acceptable and comparable to that of the general population, however viral load coverage was low. Strategies that increase retention in care and access to viral load testing such as individual client centred care models are vital to improve retention and viral load coverage among FSWs.

28 May 2022 in IJID Regions
Verified
Journal Article
Open access
LALydia Atuhaire
Lydia Atuhaire
CSConstance Shumba
Constance Shumba
LMLovemore Mapahla
Lovemore Mapahla
IMInnocent Maposa
Innocent Maposa
PNPeter S. Nyasulu
Peter S. Nyasulu
Frequent human immunodeficiency virus (HIV) testing is recommended among female sex workers. This study examined the extent to which HIV-negative female sex workers (FSWs) in Kampala adhere to the HIV testing guidelines, and identified associated factors. This cross-sectional study used a simple random sampling method to select 12 sex work hotspots. Two hundred participants were allocated proportionally in each hotspot. Frequencies were used to describe categorical characteristics of FSWs, and a multivariable logistic regression model was used to determine the factors associated with adherence to the HIV testing guidelines. Eighty-eight percent of the 200 study participants reported their HIV testing status; of these, 56% had tested three or more times in the 12 months preceding the survey. Attaining a secondary education was associated with adherence to the HIV testing guidelines [odds ratio (OR) 1.86, 95% confidence interval (CI) 1.01–3.44; P=0.047]. Sexually transmitted infection testing in the preceding 3 months (OR 2.13, 95% CI 0.95–4.74; P=0.065) and accessing HIV testing at a drop-in centre (OR 5.90, 95% CI 0.71–49.1; P=0.101) were associated with higher odds of adherence to the HIV testing guidelines. Adherence to the HIV testing guidelines was suboptimal, indicating the need to scale up interventions to improve access to HIV testing, including rigorous behaviour change communication.

13 March 2024 in PLOS ONE
Verified
Journal Article
Open access
PDF file
BEBasant Moustafa Elsayed
Basant Moustafa Elsayed
MEMohamed Salah Abdelkareem Elmarasi
Mohamed Salah Abdelkareem Elmarasi
RMRuvarashe J Madzime
Ruvarashe J Madzime
LMLovemore Mapahla
Lovemore Mapahla
MEMenatalla M S ElBadway
Menatalla M S ElBadway
TCTawanda Chivese
Tawanda Chivese
Male circumcision (MC) is a key part of the package of interventions to prevent HIV, the biggest health challenge in sub-Saharan Africa. To estimate the male circumcision prevalence and to evaluate the progress towards meeting WHO targets in sub-Saharan Africa during the period 2010–2023. We carried out a systematic review and meta-analysis of studies published during the period 2010–2023. We searched PubMed, Scopus, Cochrane CENTRAL, Google Scholar, WHO and the Demographic and Health Survey for reports on MC prevalence in sub-Saharan Africa. MC prevalence was synthesized using inverse-variance heterogeneity models, heterogeneity using I2 statistics and publication bias using funnel plots. A total of 53 studies were included. The overall prevalence during the study period was 45.9% (95% CI 32.3–59.8), with a higher MC prevalence in Eastern (69.9%, 95%CI 49.9–86.8) compared to Southern African (33.3%, 95%CI 21.7–46.2). The overall prevalence was higher in urban (45.3%, 95%CI 27.7–63.4) compared to rural settings (42.6%, 95% 26.5–59.5). Male circumcision prevalence increased from 40.2% (95% CI 25.0–56.3) during 2010–2015 to 56.2% (95% CI 31.5–79.5) during 2016–2023. Three countries exceeded 80% MC coverage, namely, Ethiopia, Kenya and Tanzania. Overall, the current MC prevalence is below 50%, with higher prevalence in Eastern African countries and substantially lower prevalence in Southern Africa. Most of the priority countries need to do more to scale up medical male circumcision programs.

31 March 2025 in Allergy
Verified
Journal Article
Open access
CDCascia Day
Cascia Day
MDMimi Deetlefs
Mimi Deetlefs
LMLovemore Mapahla
Lovemore Mapahla
YJYejin Jang
Yejin Jang
QGQiqa Gusha‐Mhlekude
Qiqa Gusha‐Mhlekude
JPJonny Peter
Jonny Peter

20 October 2025 in Frontiers in Allergy
Verified
Journal Article
Open access
PDF file
CDCascia Day
Cascia Day
LMLovemore Mapahla
Lovemore Mapahla
MRMelissa Ribeiro
Melissa Ribeiro
MDMimi Deetlefs
Mimi Deetlefs
CMCathryn McDougall
Cathryn McDougall
JPJonny Peter
Jonny Peter
Introduction: Angiotensin converting enzyme inhibitors (ACEI) have proven mortality and morbidity benefit in hypertension, ischemic heart disease, heart failure, and renal disease and are among the most prescribed medications globally. ACEI angioedema (AE-ACEI) is a potentially life-threatening adverse drug reaction that is reported to occur more frequently in African American populations. However, the clinical profile of AE-ACEI is poorly characterized in diverse African populations.Methods: A case-controlled cohort study with enrolment of AE-ACEI cases and drug-tolerant controls in Cape Town, South Africa. Univariable and multivariable analysis was performed. Controls were defined as patients tolerating ACEI for a minimum of two years. Cases were defined as patients who had angioedema while using an ACEI, patients with a history of angioedema while not on an ACEI were excluded. Cases and controls were recruited from the same demographic areas, including both hospitals and clinics. Information regarding demographics and clinical history was captured via both in person interviews and folder review.Results: A total of 237 AE-ACEI cases, and 466 ACEI tolerant controls were enrolled from seven sites in Cape Town. Features of IgE-mediated immediate drug hypersensitivity were present in 24 cases, which excluded them from analysis. The median age was 58 years (IQR: 47; 67) and 57% were female. AE-ACEI cases more frequently had Black genetic ancestry compared to controls [53% (81/154), vs. 29% (146/407), p < 0.001]. AE-ACEI occurred within 30 days of initiating ACEI therapy in only 31.1% (70/225), with median treatment time to AE-ACEI of 6.9 years (IQR: 2.9; 13). The ACEI tolerant controls were using ACEI for median 9.5 years (IQR: 5; 15.5). All AE-ACEI cases developed swelling above the shoulders, involving the lips and tongue in 72% (165/213) and 50% (107/213) cases respectively. Hospitalisation for AE-ACEI was required in 82% (175/213), however only two patients were intubated, and there were no mortalities. In multivariable analysis traditional risk factors of age, gender, immunosuppression and atopy did not differ between cases and controls. Black genetic ancestry [aOR 15.4 (95% CI 2.94–283), p value = 0.01] and calcium channel blocker use [aOR 1.77 (95% CI 1.17–2.72), p value = 0.008] were significant risk factors for developing AE-ACEI. Cardiac failure, chronic kidney disease, and statin use reduced the risk of AE-ACEI in this model.Conclusion: In this South African population, Black genetic ancestry and calcium channel blocker use were the major risk factors for AE-ACEI. The majority of AE-ACEI occurred after several years of treatment, with most cases involving the lip and/or tongue. Long-term follow-up, genetic, and further mechanistic studies are warranted in additional diverse African populations.

2 January 2025 in African Journal of AIDS Research
Verified
Journal Article
Open access
BMBilaal Wilson Matola
Bilaal Wilson Matola
LMLovemore Mapahla
Lovemore Mapahla
JNJuliet Nyasulu
Juliet Nyasulu
The HIV and AIDS epidemic remains a critical global health challenge. Malawi accounts for 2.5% of global HIV cases and is a focus country in the UNAIDS 95-95-95 fast-track initiative. Despite reaching 92-95-94 in 2020, there is a need to evaluate Malawi's progress as of 2023 to identify gaps and ensure success before the target period ends. This quantitative descriptive study used secondary data from Malawi's Department of HIV and AIDS Management Information System (DHAMIS) database over a 12-year period (2012-2023) and HIV spectrum estimates. It contains aggregate data from HIV service delivery points. Data included key HIV indicators disaggregated by age and gender. Numerators for the 95-95-95 are: people living with HIV (PLHIV) who know their status, PLHIV on treatment, PLHIV on treatment and virally suppressed. Denominators are: the estimated total PLHIV, PLHIV who know their status and PLHIV on treatment. Statistical analysis was performed using Excel, SPSS and Stata to assess differences between groups. Ethical approval and data access permissions were granted by the Ministry of Health. Between 2012 and 2023, the total number of PLHIV increased from 962 043 to 991 600. The percentage of PLHIV aware of their HIV status increased from 73% to 95%, and those on treatment increased from 58% to 95%. By 2023, 87% of children (under 15 years old) knew their HIV status, compared to 96% of adults. Lower percentages of ART initiation and viral load suppression were also noted among children. While both males and females improved across all indicators, men consistently lagged women in all three indicators. The viral suppression gap narrowed after 2019. Malawi has improved in the HIV treatment cascade between 2012 and 2023. Challenges remain in children ART initiation and access to care for men, requiring targeted efforts to achieve equitable treatment for all and meet the UNAIDS 95-95-95 targets.